Analyse court terme - NOVAVAX : Les cours progressent encore.
La tendance est haussière. Les cours progressent encore, mais la tendance s'affaiblit.La prochaine résistance est à 1,88 $. La rupture de 1,15 $ mettrait la tendance en danger.
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Using recombinant nanoparticle vaccine technology, the company produces vaccine candidates to respond to disease threats. The company's product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus and the Ebola virus, and preclinical programs for other infectious disease vaccine candidates. The company is also developing immune stimulating saponin-based adjuvants through its subsidiary, Novavax AB.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.